These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 28910270)

  • 1. Updated Dosing Instructions for Immune Globulin (Human) GamaSTAN S/D for Hepatitis A Virus Prophylaxis.
    Nelson NP
    MMWR Morb Mortal Wkly Rep; 2017 Sep; 66(36):959-960. PubMed ID: 28910270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update: Recommendations of the Advisory Committee on Immunization Practices for Use of Hepatitis A Vaccine for Postexposure Prophylaxis and for Preexposure Prophylaxis for International Travel.
    Nelson NP; Link-Gelles R; Hofmeister MG; Romero JR; Moore KL; Ward JW; Schillie SF
    MMWR Morb Mortal Wkly Rep; 2018 Nov; 67(43):1216-1220. PubMed ID: 30383742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Testing for antibody to hepatitis A to decrease the cost of hepatitis A prophylaxis with immune globulin or hepatitis A vaccines.
    Bryan JP; Nelson M
    Arch Intern Med; 1994 Mar; 154(6):663-8. PubMed ID: 8129500
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention of hepatitis A infections: guidelines for use of hepatitis A vaccine and immune globulin. American Academy of Pediatrics Committee on Infectious Diseases.
    Pediatrics; 1996 Dec; 98(6 Pt 1):1207-15. PubMed ID: 8951284
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Field effectiveness of hepatitis A vaccine and uptake of post exposure prophylaxis following a change to the Australian guidelines.
    Freeman E; Lawrence G; McAnulty J; Tobin S; MacIntyre CR; Torvaldsen S
    Vaccine; 2014 Sep; 32(42):5509-13. PubMed ID: 25111168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The indications and safety of polyvalent immunoglobulin for post-exposure prophylaxis of hepatitis A, rubella and measles.
    Young MK
    Hum Vaccin Immunother; 2019; 15(9):2060-2065. PubMed ID: 31116633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyvalent Human Immune Globulin: A Prospective, Open-Label Study Assessing Anti-Hepatitis A Virus (HAV) Antibody Levels, Pharmacokinetics, and Safety in HAV-Seronegative Healthy Subjects.
    Kankam M; Griffin R; Price J; Michaud J; Liang W; Llorens MB; Sanz A; Vince B; Vilardell D
    Adv Ther; 2020 May; 37(5):2373-2389. PubMed ID: 32301062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The optimal dose of disease-specific antibodies for post-exposure prophylaxis of measles and rubella in Australia: new guidelines recommended.
    Young MK; Ng SK; Nimmo GR; Cripps AW
    Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):663-669. PubMed ID: 29865869
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin prophylaxis for hepatitis A.
    Winokur PL; Stapleton JT
    Clin Infect Dis; 1992 Feb; 14(2):580-6. PubMed ID: 1554845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Feasibility of identifying plasma donors with high measles neutralizing antibody concentrations for the use of producing a measles hyperimmune globulin for postexposure prophylaxis.
    Lackner C; Karbiener M; Faltner L; Farcet MR; Kreil TR
    Immunol Res; 2022 Jun; 70(3):365-370. PubMed ID: 35266077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potency of fragmented IgG: two studies of postexposure prophylaxis in type A hepatitis.
    Brachott D; Lifschitz I; Mosley JW; Kendrick MA; Sgouris JT
    J Lab Clin Med; 1975 Feb; 85(2):281-6. PubMed ID: 122995
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serological study of hepatitis A virus infection amongst the students of a medical college in Delhi & evaluation of the need of vaccination.
    Jindal M; Rana SS; Gupta RK; Das K; Kar P
    Indian J Med Res; 2002 Jan; 115():1-4. PubMed ID: 12424929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Financial Burden of Public Health Responses to Hepatitis A Cases Among Food Handlers, 2012-2014.
    Morey RJ; Collier MG; Nelson NP
    Public Health Rep; 2017; 132(4):443-447. PubMed ID: 28609202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of previous hepatitis A virus infection in renal transplant patients with hepatitis C: evidence of persistent anti-hepatitis A virus immune response.
    Mariya FA; de Mello Perez R; Silva AE; Pestana JO; Ferraz ML
    Transplant Proc; 2004 Jun; 36(5):1500-1. PubMed ID: 15251370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis A vaccine versus immune globulin for postexposure prophylaxis.
    Victor JC; Monto AS; Surdina TY; Suleimenova SZ; Vaughan G; Nainan OV; Favorov MO; Margolis HS; Bell BP
    N Engl J Med; 2007 Oct; 357(17):1685-94. PubMed ID: 17947390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunoglobulin prophylaxis against hepatitis A among Swedish UN soldiers in an endemic region.
    Weiland O; Berg JV; Bäck E; Lundbergh P
    Infection; 1979; 7(5):223-5. PubMed ID: 511340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. Updated recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Advisory Committee on Immunization Practices (ACIP) Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2007 Oct; 56(41):1080-4. PubMed ID: 17947967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of universal toddlers-only hepatitis A virus vaccination program on seropositivity rate in unvaccinated toddlers: evidence for reduced virus circulation in the community.
    Barkai G; Belmaker I; Givon-Lavi N; Dagan R
    Pediatr Infect Dis J; 2009 May; 28(5):391-3. PubMed ID: 19295466
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficient neutralizing activity of cocktailed recombinant human antibodies against hepatitis A virus infection in vitro and in vivo.
    Cao J; Meng S; Li C; Ji Y; Meng Q; Zhang Q; Liu F; Li J; Bi S; Li D; Liang M
    J Med Virol; 2008 Jul; 80(7):1171-80. PubMed ID: 18461629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic modeling to determine the minimum effective dose of disease-specific antibodies for preventing hepatitis A post-exposure.
    Young MK; Ng SK; Nimmo GR; Cripps AW
    Expert Opin Drug Metab Toxicol; 2020 Jul; 16(7):641-644. PubMed ID: 32362179
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.